协同创新对医药制造业创新绩效的影响研究

Research on the Impact of Collaborative Innovation on the Innovation Performance of Pharmaceutical Manufacturing Industry

摘要:

协同创新是提高产业创新绩效的有效途径。本文以医药制造业为研究对象，从政府、产业、高校和研究机构三个层面出发，采用fsQCA方法分析三重螺旋协同创新系统驱动产业创新绩效的关键因素与条件组合，为具备不同资源条件的地区提供产生高产业创新绩效的路径参考。研究结果表明:（1）具备高校专业基础构成了高产业创新绩效的必要条件，同时在产生高创新绩效的等效路经中均包含了高产业技术创新这一核心条件。（2）存在4条实现高产业创新绩效的路径，本文归纳概括为“产学协同共驱型”“产业主导弥补型”和“官产学合作发展型”3种驱动模式。（3）“产学协同共驱型”驱动路径表明:在产学基础较完备的情况下，辅之以积极的政府政策发布能够形成高创新绩效；而如果一定程度上缺乏政府经济支持，同样也能推动医药制造业产业高创新绩效的形成。（4）“产业主导弥补型”驱动路径表明:强劲的产业技术创新和稳固的高校专业基础，能够弥补政府在经济支持与政策支撑方面表现欠缺，从而推动医药制造业产业高创新绩效的形成。（5）“官产学合作发展型”驱动路径表明:不仅产业技术创新能力强，而且政府经济支持有力、研究机构投入强劲、高校专业基础稳固，产业研发投入的欠缺并不影响医药制造业产业高创新绩效的形成。

Abstract:

Collaborative innovation is an effective way to improve the performance of industrial innovation. This article takes the pharmaceutical manufacturing industry as the research object. Using the fsQCA method, starting from the three levels of government, industry, universities, and research institutions, it analyzes the key factors and condition combinations of the triple helix collaborative innovation system driving industrial innovation performance, providing a path reference for regions with different resource conditions to generate high industrial innovation performance. The research results indicate that: (1) Having a professional foundation in universities is a necessary condition for high industrial innovation performance, and the core condition of high industrial technological innovation is included in the equivalent path of generating high innovation performance. (2) There are four paths to achieve high industrial innovation performance, which can be summarized in this article as three driving models: "industry academia collaborative driving" "industry led compensation", and "official industry academia cooperative development". (3) The driving path of "industry academia collaborative driving" indicates that, in the case of a relatively complete industry academia foundation, active government policy release can form high innovation performance; If there is a certain lack of government economic support, it can also promote the formation of high innovation performance in the pharmaceutical manufacturing industry. (4) The driving path of "industry driven compensation" indicates that strong industrial technological innovation and a solid foundation of university majors can compensate for the government"s lack of economic and policy support, thereby promoting the formation of high innovation performance in the pharmaceutical manufacturing industry. (5) The driving path of "government industry university cooperation development" indicates that not only does it have strong industrial and technological innovation capabilities, but also strong government economic support, strong investment in research institutions, and stable professional foundations in universities. The lack of investment in industrial research and development does not affect the formation of high innovation performance in the pharmaceutical manufacturing industry.